Vera Therapeutics (VERA) Receivables - Accured (2023 - 2026)

Vera Therapeutics' Receivables - Accured history runs 4 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• Quarterly Receivables - Accured rose 8.98% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 8.98% YoY) and the FY2025 annual result came in at $3.3 million, down 12.93% from the prior year.
• Receivables - Accured was $3.9 million for Q1 2026 at Vera Therapeutics, up from $3.3 million in the prior quarter.
• Across five years, Receivables - Accured topped out at $4.2 million in Q2 2025 and bottomed at $512000.0 in Q4 2023.
• A 4-year average of $2.8 million and a median of $3.3 million in 2025 frame the typical range for Receivables - Accured.
• Annual changes were most pronounced in 2024 — Receivables - Accured soared 636.91% — and 2025, when it slipped 12.93%.
• Vera Therapeutics' Receivables - Accured stood at $512000.0 in 2023, then surged by 636.91% to $3.8 million in 2024, then dropped by 12.93% to $3.3 million in 2025, then gained by 18.96% to $3.9 million in 2026.
• Business Quant data shows VERA's Receivables - Accured at $3.9 million in Q1 2026, $3.3 million in Q4 2025, and $3.4 million in Q3 2025.